A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)...
AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)
RGX-202 is a gene therapy designed to deliver a transgene for a novel microdystrophin that includes functional elements of naturally-occurring dystrophin including the C-Terminal (CT) domain. This is...
A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)
The purpose of this study is to assess the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of satralizumab, a humanized anti-interleukin-6 receptor (aIL-6R) monoclonal antibody, in a...
A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)
This is a multicenter, open-label, non-randomized study to investigate the safety, tolerability, and efficacy of a single intravenous (IV) infusion of SGT-003 in participants with Duchenne muscular dy...
Once Weekly Infant Corticosteroid Trial for DMD
The hypothesis tested here is that a lower dose of intermittent oral corticosteroids (5mg/kg/week) will be equally effective to the 10mg/kg/week dose....
NS-050/NCNP-03 in Boys With DMD (Meteor50)
This is a Phase 1/2 study of Multiple-Ascending Dose (MAD) levels for 12 weeks of treatment followed by 24 weeks of open-label treatment with a selected dose of NS-050/NCNP-03 administered once weekly...
NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)
This is a Phase 2, open-label, multi-center, 2-part study of NS-089/NCNP-02 administered by weekly IV infusion to ambulant boys aged ≥4 to \<15 years with DMD due to mutations amenable to exon 44 skip...
A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy
The goal of this clinical trial is to learn how safe and tolerable EPI-321 is and whether there may be early signs it is working in male or female adult (18 to 75 years) participants with facioscapulo...
Top Cities for Duchenne Muscular Dystrophy Clinical Trials
Duchenne Muscular Dystrophy clinical trials are recruiting across 39 cities. Here are the cities with the most active studies:
About Duchenne Muscular Dystrophy
Duchenne muscular dystrophy is a severe genetic disorder characterized by progressive muscle degeneration and weakness, primarily affecting boys. It is caused by mutations in the dystrophin gene. Treatment includes corticosteroids, gene therapies, and supportive care to maintain mobility and function.
Clinical trials are advancing new treatments for duchenne muscular dystrophy. Currently, 8 studies are recruiting a combined 430 participants across the United States. Research is being conducted by 7 organizations including Avidity Biosciences, Inc., REGENXBIO Inc., Hoffmann-La Roche and 4 others.
2026 Duchenne Muscular Dystrophy Research Landscape
As of March 2026, the duchenne muscular dystrophy clinical trial landscape includes 8 actively recruiting studies across 39 cities in the United States. These studies are collectively seeking 430 participants, with an average enrollment target of 54 per study.
Research is being led by 7 different organizations, including Avidity Biosciences, Inc., REGENXBIO Inc., Hoffmann-La Roche, Solid Biosciences Inc., Anne M. Connolly, and 2 others.
Geographically, duchenne muscular dystrophy trials are most concentrated in Atlanta, Georgia (5 trials); Chicago, Illinois (5 trials); Worcester, Massachusetts (4 trials); Kansas City, Kansas (3 trials); Little Rock, Arkansas (3 trials) and 7 other cities.
Featured Duchenne Muscular Dystrophy Studies
Highlighted recruiting studies for duchenne muscular dystrophy, selected by enrollment size and research scope.
A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)
AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)
RGX-202 is a gene therapy designed to deliver a transgene for a novel microdystrophin that includes functional elements of naturally-occurring dystrophin including the C-Terminal (CT) domain. This is a multicenter, open-label dose evaluation clinical study to assess the safety, tolerability, and clinical efficacy of a one-time intravenous (IV) dose of RGX-202 in participants with Duchenne. For a...
A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)
The purpose of this study is to assess the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of satralizumab, a humanized anti-interleukin-6 receptor (aIL-6R) monoclonal antibody, in ambulatory and non-ambulatory participants with DMD age ≥ 8 to \< 18 years old receiving corticosteroid therapy.
Frequently Asked Questions About Duchenne Muscular Dystrophy Clinical Trials
Are there duchenne muscular dystrophy clinical trials near me?
Yes, there are 8 duchenne muscular dystrophy clinical trials currently recruiting across 39+ cities in the United States, including Atlanta, Georgia; Chicago, Illinois; Worcester, Massachusetts. Browse the studies above to find one at a location convenient for you.
How do I join a duchenne muscular dystrophy clinical trial?
To join a duchenne muscular dystrophy clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are duchenne muscular dystrophy clinical trials free?
Yes, participation in duchenne muscular dystrophy clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of duchenne muscular dystrophy treatments are being studied?
Current duchenne muscular dystrophy clinical trials are testing a range of approaches. These include new drugs, combination therapies, medical devices, and other interventions sponsored by 7 research organizations.
Is it safe to participate in duchenne muscular dystrophy clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated March 1, 2026 from ClinicalTrials.gov
About This Data
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated March 1, 2026 · Data from ClinicalTrials.gov